Search results for "Intestinal"

showing 10 items of 2024 documents

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Withou…

2016

International audience; BACKGROUND & AIMS: Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed the safety and efficacy of elafibranor in an international, randomized, double-blind placebo-controlled trial of patients with nonalcoholic steatohepatitis (NASH).METHODS: Patients with NASH without cirrhosis were randomly assigned to groups given elafibranor 80 mg (n = 93), elafibranor 120 mg (n = 91), or placebo (n = 92) each day for 52 weeks at sites in Europe and the United States. Clinical and …

0301 basic medicineLiver CirrhosisMaleTime FactorsIntention to Treat Analysi[SDV]Life Sciences [q-bio]BiopsyPLACEBO-CONTROLLED TRIALTHERAPYGastroenterologySeverity of Illness IndexChalcone0302 clinical medicineChalconesNon-alcoholic Fatty Liver DiseaseGastrointestinal AgentNonalcoholic fatty liver diseasePropionateMedicine and Health SciencesOdds RatioMedicineGlucose homeostasisVITAMIN-Eeducation.field_of_studyGastrointestinal agentFatty liverRemission InductionGastroenterologyMiddle Aged3. Good healthIntention to Treat AnalysisPPARDEuropeTreatment OutcomeLiverACIDPIOGLITAZONE030211 gastroenterology & hepatologyFemalePPARAHumanSignal TransductionAdultCLINICAL-OUTCOMESmedicine.medical_specialtyLogistic ModelTime FactorLiver CirrhosiPopulationfatty liver; NAFLD; PPARA; PPARD; Adult; Biomarkers; Biopsy; Chalcones; Double-Blind Method; Europe; Female; Gastrointestinal Agents; Humans; Intention to Treat Analysis; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Odds Ratio; PPAR alpha; PPAR gamma; Propionates; Remission Induction; Severity of Illness Index; Signal Transduction; Time Factors; Treatment Outcome; United States; GastroenterologyPlacebo03 medical and health sciencesDouble-Blind MethodGastrointestinal AgentsInternal medicineNAFLDHumansPPAR alphaeducationFATTY LIVER-DISEASEfatty liverHepatologybusiness.industryBiomarkerAMERICAN ASSOCIATIONOdds ratiomedicine.diseaseConfidence intervalUnited StatesPPAR gammaRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]030104 developmental biologyEndocrinologyLogistic ModelsHuman medicinePropionatesbusinessBiomarkers
researchProduct

Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival.

2021

Background & Aims Transjugular intrahepatic portosystemic shunt (TIPS) implantation is an effective and safe treatment for complications of portal hypertension. Survival prediction is important in these patients as they constitute a high-risk population. Therefore, the aim of our study was to develop an alternative prognostic model for accurate survival prediction after planned TIPS implantation. Methods A total of 1,871 patients with de novo TIPS implantation for ascites or secondary prophylaxis of variceal bleeding were recruited retrospectively. The study cohort was divided into a training set (80% of study patients; n = 1,496) and a validation set (20% of study patients; n = 375). Furth…

0301 basic medicineLiver CirrhosisMalemedicine.medical_specialtyCirrhosismedicine.medical_treatmentPopulationClinical Decision-MakingSerum Albumin HumanEsophageal and Gastric Varices03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineAscitesmedicineSecondary PreventionHumanseducationAgedRetrospective Studieseducation.field_of_studyFramingham Risk ScoreHepatologyProportional hazards modelbusiness.industryAge FactorsAscitesBilirubinMiddle Agedmedicine.diseasePrognosisSurvival Rate030104 developmental biologyTreatment OutcomeResearch DesignCreatinineCohortPortal hypertension030211 gastroenterology & hepatologyFemalemedicine.symptomPortasystemic Shunt Transjugular IntrahepaticbusinessGastrointestinal HemorrhageTransjugular intrahepatic portosystemic shuntJournal of hepatology
researchProduct

Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1

2019

Long noncoding RNAs (lncRNAs) are emerging as key regulators of genetic and epigenetic networks, and their deregulation may underlie complex diseases, such as carcinogenesis. Several studies described lncRNA alterations in patients with solid tumors. In particular, HOTAIR upregulation has been associated with tumor aggressiveness, metastasis, and poor survival in gastrointestinal stromal tumor (GIST) patients. We analyzed expression levels of other lncRNAs, H19 and MALAT1, in FFPE tissue specimens from 40 surgically resected and metastatic GIST patients, using real-time PCR analysis. H19 and MALAT1 were both upregulated in 50% of GIST patients. MALAT1 lncRNA expression levels seem to be cor…

0301 basic medicineMALAT1long non coding RNAs H19 MALAT1Article SubjectGiSTbusiness.industryHOTAIRlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasemedicine.disease_causelcsh:RC254-282Metastasis03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyDownregulation and upregulation030220 oncology & carcinogenesisCancer researchmedicineGastrointestinal stromal tumors (GISTs)Stromal tumorCarcinogenesisbusinessResearch ArticleJournal of Oncology
researchProduct

ERK3/MAPK6 controls IL-8 production and chemotaxis

2020

ERK3 is a ubiquitously expressed member of the atypical mitogen activated protein kinases (MAPKs) and the physiological significance of its short half-life remains unclear. By employing gastrointestinal 3D organoids, we detect that ERK3 protein levels steadily decrease during epithelial differentiation. ERK3 is not required for 3D growth of human gastric epithelium. However, ERK3 is stabilized and activated in tumorigenic cells, but deteriorates over time in primary cells in response to lipopolysaccharide (LPS). ERK3 is necessary for production of several cellular factors including interleukin-8 (IL-8), in both, normal and tumorigenic cells. Particularly, ERK3 is critical for AP-1 signaling…

0301 basic medicineMAPK/ERK pathwayMouseQH301-705.5ScienceERK3General Biochemistry Genetics and Molecular BiologyCell Line03 medical and health sciencesMice0302 clinical medicineOrganoidmetastasisAnimalsHumansInterleukin 8Biology (General)chemotaxisMitogen-Activated Protein Kinase 6Gene knockdownGeneral Immunology and MicrobiologyIL-8ChemistryKinaseGeneral NeuroscienceQInterleukin-8RChemotaxisGeneral MedicineCell BiologyMAPKgastrointestinal organoidsIn vitroCell biologysecretomeChemotaxis Leukocyte030104 developmental biologyGene Expression Regulation030220 oncology & carcinogenesisMedicineHeterograftsSignal transductionsignal transductionResearch ArticleHumaneLife
researchProduct

Trends of extended-spectrum β-lactamase-producing Escherichia coli sequence type 131 and its H30 subclone in a French hospital over a 15-year period.

2016

International audience; Sequence type 131 (ST131) is a predominant lineage among extraintestinal pathogenic Escherichia coli. It plays a major role in the worldwide dissemination of E. coli producing extended-spectrum β-lactamases (ESBLs). Here we describe the long-term epidemiology of this clonal group in a French university hospital, where the incidence of ESBL-producing E. coli has increased from 0.018 case per 1000 patient-days in the year 2000 to 0.50 case per 1000 patient-days in 2014. The first of the 141 ST131 isolates was recovered in 2006, and the ST131 clonal group accounted for 18.1% of total ESBL-producing E. coli over the whole period (2000-2014). Subclonal typing showed that …

0301 basic medicineMESH : Escherichia coliMESH : Retrospective StudiesMESH : Multilocus Sequence TypingMESH: beta-LactamasesMESH : GenotypeMultidrug resistancemedicine.disease_causeHospitals UniversityMESH: Genotype[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyPharmacology (medical)MESH: IncidenceMESH: Genetic VariationEscherichia coli InfectionsComputingMilieux_MISCELLANEOUSCross InfectionMolecular EpidemiologyExtraintestinal Pathogenic Escherichia coliMESH: Escherichia coliIncidenceIncidence (epidemiology)MESH : beta-LactamasesGeneral MedicinePFGEMESH : IncidenceElectrophoresis Gel Pulsed-Field3. Good healthInfectious DiseasesMESH: Electrophoresis Gel Pulsed-FieldMESH: Multilocus Sequence Typing[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyMESH : Escherichia coli Infections[SDE]Environmental SciencesFranceMESH : Cross InfectionMicrobiology (medical)clone (Java method)Lineage (genetic)GenotypeMESH : Molecular Epidemiology030106 microbiologyBiologybeta-LactamasesMicrobiology03 medical and health sciencesExtended-spectrum β-lactamaseMESH : Genetic VariationEscherichia coliPulsed-field gel electrophoresismedicineHumansMESH: Molecular EpidemiologyTypingMESH : FranceEscherichia coliMESH : Hospitals UniversityRetrospective StudiesMESH : Electrophoresis Gel Pulsed-FieldMESH: Escherichia coli InfectionsMESH: Hospitals UniversityMESH: HumansMESH : HumansGenetic VariationMESH: Cross InfectionMESH: Retrospective Studiesbacterial infections and mycosesMultiple drug resistanceMESH: FranceESBLMultilocus Sequence Typing
researchProduct

The IgGFc-binding protein FCGBP is secreted with all GDPH sequences cleaved but maintained by interfragment disulfide bonds

2021

Mucus forms an important protective barrier that minimizes bacterial contact with the colonic epithelium. Intestinal mucus is organized in a complex network with several specific proteins, including the mucin-2 (MUC2) and the abundant IgGFc-binding protein, FCGBP. FCGBP is expressed in all intestinal goblet cells and is secreted into the mucus. It is comprised of repeated von Willebrand D (vWD) domain assemblies, most of which have a GDPH amino acid sequence that can be autocatalytically cleaved, as previously observed in the mucins MUC2 and mucin-5AC. However, the functions of FCGBP in the mucus are not understood. We show that all vWD domains of FCGBP with a GDPH sequence are cleaved and …

0301 basic medicineMUC5AC mucin-5ACMUC2 mucin-2 (Muc2 mouse)vWF von Willebrand factorBiochemistryvon Willebrand domainchemistry.chemical_compoundPVDF polyvinylidene difluorideMiceCricetinaeDisulfidesIntestinal MucosaPeptide sequenceEndoH endoglycosidase HbiologyChemistryrespiratory systemGDPH Gly-Asp-Pro-HisChaotropic agentBiochemistryWB Western blotIodoacetamideGuHCl guanidinium chlorideResearch ArticleIgG immunoglobulin GvWD von Willebrand D domainCHO CellsCHO Chinese hamster ovary03 medical and health sciencesEndoglycosidase HCricetulusProtein Domainsmucusvon Willebrand FactorAnimalsHumansintestinal epitheliumMolecular BiologyintestineFCGBP IgGFc-binding protein (Fcgbp mouse)GAPH Gly-Ala-Pro-HisMucin-2030102 biochemistry & molecular biologycolonBinding proteinEndoplasmic reticulumMucinITH3 inter-alpha-trypsin inhibitor heavy chain 3Cell BiologyMucusMice Inbred C57BL030104 developmental biologyMUC2Proteolysisbiology.proteinImmunoglobulin G (IgG)IAA iodoacetamideCell Adhesion MoleculesdisulfideThe Journal of Biological Chemistry
researchProduct

Gut inflammation in spondyloarthritis

2017

Abstract Spondyloarthritis (SpA) is a group of related diseases sharing common etiopathogenic mechanisms and clinical manifestations supported by a complex genetic predisposition. Gut inflammation is present in patients with SpA including patients showing clinically evident intestinal inflammation in the form of Crohn's disease or ulcerative colitis and patients who despite the absence of signs and symptoms of intestinal inflammation display a subclinical gut inflammation. Emerging evidence suggests that subclinical gut inflammation in patients with SpA, apparently driven by intestinal dysbiosis, is not the consequence of the systemic inflammatory process but rather an important pathophysio…

0301 basic medicineMacrophageSpondyloarthropathyInflammationSystemic inflammationPathogenesis03 medical and health sciences0302 clinical medicineRheumatologySpondylarthritismedicineHumansInnate lymphoid cellCytokineGut inflammationSubclinical infection030203 arthritis & rheumatologyInnate immunityInflammationAnkylosing spondylitisbusiness.industryInnate lymphoid cellPsoriatic arthritimedicine.diseaseUlcerative colitisDysbiosiGastrointestinal MicrobiomeIntestineIntestinesAnkylosing spondylitiSettore MED/16 - Reumatologia030104 developmental biologyImmunologymedicine.symptombusinessDysbiosisHuman
researchProduct

Gut Bacteria Metabolism Impacts Immune Recovery in HIV-infected Individuals.

2016

While changes in gut microbial populations have been described in human immuno-deficiency virus (HIV)-infected patients undergoing antiretroviral therapy (ART), the mechanisms underlying the contributions of gut bacteria and their molecular agents (metabolites and proteins) to immune recovery remain unexplored. To study this, we examined the active fraction of the gut microbiome, through examining protein synthesis and accumulation of metabolites inside gut bacteria and in the bloodstream, in 8 healthy controls and 29 HIV-infected individuals (6 being longitudinally studied). We found that HIV infection is associated to dramatic changes in the active set of gut bacteria simultaneously alter…

0301 basic medicineMale030106 microbiologylcsh:MedicineInflammationHIV InfectionsGut microbiotaGut floraGeneral Biochemistry Genetics and Molecular BiologyVirusMicrobiology03 medical and health sciencesMedicine General & InternalImmunityAntiretroviral Therapy Highly ActivemedicineMetabolomeHumansMetabolomicsImmune recoveryBiologyMetaproteomelcsh:R5-920biologyBacteriaGastrointestinal Microbiomelcsh:RImmunityHIVGeneral MedicineViral Loadbiology.organism_classificationCD4 Lymphocyte CountGastrointestinal MicrobiomeAntiretroviral therapy030104 developmental biologyCase-Control StudiesImmunologyHIV-1MetabolomeFemalemedicine.symptomlcsh:Medicine (General)Viral loadBacteriaBiomarkersResearch PaperEBioMedicine
researchProduct

Gut microbiota differs between children with Inflammatory Bowel Disease and healthy siblings in taxonomic and functional composition: a metagenomic a…

2017

Current treatment for pediatric inflammatory bowel disease (IBD) patients is often ineffective, with serious side effects. Manipulating the gut microbiota via fecal microbiota transplantation (FMT) is an emerging treatment approach but remains controversial. We aimed to assess the composition of the fecal microbiome through a comparison of pediatric IBD patients to their healthy siblings, evaluating risks and prospects for FMT in this setting. A case-control (sibling) study was conducted analyzing fecal samples of six children with Crohn’s disease (CD), six children with ulcerative colitis (UC) and 12 healthy siblings by metagenomic sequencing. In addition, lifetime antibiotic intake was r…

0301 basic medicineMaleAdolescentPhysiologyGut floraMicrobial dysbiosisInflammatory bowel disease03 medical and health sciencesFecesYoung Adult0302 clinical medicinePhysiology (medical)medicineHumansMicrobiomeSiblingIntestinal MucosaChildHepatologybiologyShotgun sequencingSiblingsGastroenterologymedicine.diseasebiology.organism_classification16S ribosomal RNAInflammatory Bowel DiseasesGastrointestinal Microbiome030104 developmental biologyMetagenomicsCardiovascular and Metabolic DiseasesImmunologyMetagenome030211 gastroenterology & hepatologyFemaleAmerican journal of physiology. Gastrointestinal and liver physiology
researchProduct

Effects of a Lactobacillus salivarius mixture on performance, intestinal health and serum lipids of broiler chickens

2017

The ban or severe restriction on the use of antibiotics in poultry feeds to promote growth has led to considerable interest to find alternative approaches. Probiotics have been considered as such alternatives. In the present study, the effects of a Lactobacillus mixture composed from three previously isolated Lactobacillus salivarius strains (CI1, CI2 and CI3) from chicken intestines on performance, intestinal health status and serum lipids of broiler chickens has been evaluated. Supplementation of the mixture at a concentration of 0.5 or 1 g kg-1 of diet to broilers for 42 days improved body weight, body weight gain and FCR, reduced total cholesterol, LDL-cholesterol and triglycerides, inc…

0301 basic medicineMaleAntibioticsBlood lipidslcsh:MedicineWeight GainBiochemistryPoultrylaw.inventionProbioticRandom AllocationlawLactobacillusMedicine and Health SciencesGamefowlFood sciencelcsh:ScienceBifidobacteriumGlucuronidaseMultidisciplinarybiologyLactobacillus salivariusbeta-Glucosidasefood and beveragesAgriculture04 agricultural and veterinary sciencesLipidsIntestinesCholesterolVertebratesAnatomyResearch Articleanimal structuresmedicine.drug_classReal-Time Polymerase Chain ReactionMicrobiologyBirds03 medical and health sciencesmedicineAnimalsNutritionBacteriaProbioticslcsh:RGut Bacteria0402 animal and dairy scienceBroilerOrganismsBiology and Life Sciencesbiology.organism_classification040201 dairy & animal scienceAnimal FeedDietGastrointestinal MicrobiomeGastrointestinal TractLactobacillus030104 developmental biologyFowlAmniotesLigilactobacillus salivariuslcsh:QBifidobacteriumChickensDigestive SystemBacteriaPLoS ONE
researchProduct